George steps aside as CEO at Clinigen to make room for Chilton

Clinigen CEO-elect Shaun Chilton

After helming specialty pharmaceutical company Clinigen for the past 6 years, Peter George is stepping aside as chief executive to make room for Shaun Chilton, who has served as deputy chief executive for the past two years.

George, who helped establish the company in 2010, guide it through a public offering and position Clinigen as a market leader, will stay on as a non-executive director. Previous to his role as deputy CEO, Chilton served as the company’s COO.

“I’ve worked closely with Shaun over the years and look forward to supporting him as he takes the business to the next stage,” George said in a statement. “It has been a pleasure and privilege to create and lead Clinigen.”

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

During George’s tenure, Clinigen saw its revenues climb from $27 million in 2010 to $443 million this year and its share price increased more than threefold. 

“Our focus now is to drive sustainable growth by capitalizing on our market leading positions in clinical trial services and unlicensed medicines and continuing to expand our portfolio of specialty pharmaceuticals,” Chilton said.

Additionally, the company announced that Robin Sibson will retire from the board in November.

Clinigen currently has 5 divisions that source drugs for use as comparators in clinical trials, supply medicines to patients in countries where the product is not licensed or in short supply and provide medicines which are in clinical trials to doctors and hospitals for use in patients who have failed to respond to all other available treatments.

Clinigen also purchases drugs from third parties that have the potential to for a new market to treat diseases.

- check out the release

Related Articles:
UPDATED: Atlantic Healthcare closes $24M round and gains Salix founder as new CSA 
VC hits a high for U.K. biotech, but 'dark spots' remain 


Suggested Articles

CTI Clinical Trial and Consulting Services is buying up fellow CRO Clinart to deepen its reach in the Middle Eastern and Northern African regions.

Viva Biotech is putting down $80 million to buy preclinical contract research organization SYNthesis and boost its outsourcing business.

Popular research network provider TriNetX has seen major interest from The Carlyle Group as it buys up a majority stake in the company.